Efficacy and safety of antiviral plus anti-spike monoclonal antibody combination therapy vs. monotherapy for high-risk immunocompromised patients with mild-to-moderate SARS-CoV2 infection during the Omicron era: A prospective cohort studyJorge Calderón‐Parra, Elena Múñez, Gerard Ronda-Roca et al.|International Journal of Antimicrobial Agents|2024Cited by 18